ArticleCancer biology & therapy2026
Diagnostic and prognostic value of lncSPATA8-AS1 in prostate cancer and its regulatory effect on tumor progression.
Article in Cancer biology & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong noncoding RNAs (lncRNAs) have significant impacts on the occurrence and development of many cancers. However, their effects and mechanisms on prostate cancer (PCa) remain largely unknown. The study was to explore the influence of lncSPATA8-AS1 on PCa and its molecular mechanism of action.
methodsIn the GSE179321 dataset, lncSPATA8-AS1, which was upregulated in PCa tumor tissues, was selected. The expression levels of lncSPATA8-AS1, miR-328-5p, and EPHB2 were detected using RT-qPCR.
resultsLncSPATA8-AS1 was upregulated in PCa tissues, serum, and cell lines. Clinically, lncSPATA8-AS1 could serve as a biomarker for the diagnosis and prognosis of PCa. Silencing lncSPATA8-AS1 can inhibit the cell viability of PCa tumor cells, suppress epithelial-mesenchymal transformation (EMT), cell migration, and invasion. Mechanistically, lncSPATA8-AS1 affects the expression of EPHB2 by interacting with miR-653-5p, thereby regulating the malignant biological behavior of PCa.
conclusionThe expression of lncSPATA8-AS1 is upregulated in the serum of PCa patients, and it has great potential as a biomarker for the diagnosis and prognosis of PCa. The lncSPATA8-AS1/miR-328-5p/EPHB2 axis drives the malignant biological behavior of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.